M
Mohane Selvaraj Coumar
Researcher at Pondicherry University
Publications - 106
Citations - 2540
Mohane Selvaraj Coumar is an academic researcher from Pondicherry University. The author has contributed to research in topics: Aurora inhibitor & Virtual screening. The author has an hindex of 26, co-authored 100 publications receiving 2126 citations. Previous affiliations of Mohane Selvaraj Coumar include Panjab University, Chandigarh & Central University, India.
Papers
More filters
Journal ArticleDOI
Treat cancers by targeting survivin: Just a dream or future reality?
Mohane Selvaraj Coumar,Fang Ying Tsai,Jagat R. Kanwar,Sailu Sarvagalla,Chun Hei Antonio Cheung +4 more
TL;DR: Despite the growing amount of knowledge related to survivin in the last ten years, the development of survivin inhibitors or survivin-related molecular therapies is surprisingly and relatively slow as compared to other therapeutic inhibitors for cancer treatment.
Journal ArticleDOI
Anti-influenza drug discovery: structure-activity relationship and mechanistic insight into novel angelicin derivatives.
Jiann Yih Yeh,Mohane Selvaraj Coumar,Jim-Tong Horng,HY Shiao,HY Shiao,Fu Ming Kuo,Hui Ling Lee,In Chun Chen,Chun Wei Chang,Wen Fang Tang,Sung Nain Tseng,Chi Jene Chen,Shin-Ru Shih,John T.A. Hsu,John T.A. Hsu,Chun-Chen Liao,Chun-Chen Liao,Yu-Sheng Chao,Hsing Pang Hsieh +18 more
TL;DR: Preliminary mechanistic studies suggest that these compounds act as anti-influenza agents by inhibiting ribonucleoprotein (RNP) complex associated activity and have the potential to be developed further, which could form the basis for developing additional defense against influenza pandemics.
Journal ArticleDOI
Design and synthesis of tetrahydropyridothieno[2,3-d]pyrimidine scaffold based epidermal growth factor receptor (EGFR) kinase inhibitors: the role of side chain chirality and Michael acceptor group for maximal potency.
Chia Hsien Wu,Mohane Selvaraj Coumar,Chang Ying Chu,Wen-Hsing Lin,Yi-Rong Chen,Chiung-Tong Chen,Hui Yi Shiao,Shaik Rafi,Sing Yi Wang,Hui Hsu,Chun Hwa Chen,Chun Yu Chang,Teng Yuan Chang,Tzu Wen Lien,Ming Yu Fang,Kai-Chia Yeh,Ching Ping Chen,Teng Kuang Yeh,Su Huei Hsieh,John T.A. Hsu,Chun-Chen Liao,Chun-Chen Liao,Yu-Sheng Chao,Hsing Pang Hsieh +23 more
TL;DR: HTS hit 7 was modified through hybrid design strategy to introduce a chiral side chain followed by introduction of Michael acceptor group to obtain potent EGFR kinase inhibitors 11 and 19, which inhibited gefitinib-resistant double mutant (DM, T790M/L858R) EGFRKinase at nanomolar concentration.
Journal ArticleDOI
Evolutionary algorithms for de novo drug design - A survey
TL;DR: Various tools using evolutionary algorithm, a soft computing technique for multi-objective optimization to find novel molecules for drug development are surveyed and analyzed in detail, with particular emphasis on the computational aspects.
Journal ArticleDOI
Aurora kinase inhibitors in preclinical and clinical testing
TL;DR: Considering the fact that aurora kinase plays an important role in the mitosis process and is involved in tumorigenesis, development of aurora Kinase inhibitors for the treatment of cancer, either as a single agent or in combination with existing cancer treatment is warranted.